Duy tr s dng u n trong t nht 2 3 thng
Hanney SR, Castle-Clarke S, Grant J, et al
More on returns and refunds Your purchases on commercioVirtuoso.it are covered by the marketplace guarantee
Setmelanotide Setmelanotide is a melanocortin-4 receptor (MC4R) agonist approved to treat genetic obesity due to pro-opiomelanocortin (POMC), proprotein convertase subtilisin/kexin type 1 (PCSK1), or leptin receptor (LEPR) deficiencies, as well as BardetBiedl syndrome (BBS), in patients aged 2 years and older [45,46,47]
2013 Jan 31;2013(1):CD000980
The candidate has previously advanced through Phase IIa clinical evaluation in obese patients, as well as Phase I single ascending dose (SAD) studies in healthy volunteers and multiple ascending dose (MAD) studies in diabetic patients